Provider: Ingenta Connect
Database: Ingenta Connect
Content: application/x-research-info-systems
TY - ABST
AU - Urueña, Analía
AU - González, Jorge E.
AU - Rearte, Analía
AU - Pérez Carrega, María E.
AU - Calli, Rogelio
AU - Pagani, María F.
AU - Uboldi, Andrea
AU - Vicentín, Rosalía
AU - Caglio, Patricia
AU - Cañero-Velasco, María C.
AU - Gentile, Angela
AU - Ramonet, Margarita
AU - Vizzotti, Carla
TI - Single-dose Universal Hepatitis A Immunization in One-year-old Children in Argentina
JO - The Pediatric Infectious Disease Journal
PY - 2016-12-01T00:00:00///
VL - 35
IS - 12
SP - 1339
EP - 1342
KW - children
KW - immunogenicity
KW - long-term follow-up
KW - Argentina
KW - hepatitis A
KW - single-dose vaccination
N2 -
Background:
Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children 12 months of age in 2005. Previous studies demonstrated high prevalence of protective antibody response 4 years after single-dose vaccination. This study assessed long-term
seroprotection against HAV after vaccination.
Methods:
Children who received 1 dose of HAV vaccine at 1 year of age at least 6 years before enrollment were included at 5 centers in Argentina between 2013 and 2014. Demographic and socioeconomic characteristics were collected
through a questionnaire. Blood samples were tested for anti-HAV antibodies. Antibody values ≥10 mIU/mL were considered seroprotective. Logistic regression analysis was performed to evaluate the association between demographic and socioeconomic variables and seroprotection.
Results:
A total of 1088 children were included, with a median postvaccination interval of 7.7 years (range 6.3–9.2 years). Of these children, 97.4% (95% confidence interval: 96.3%–98.3%) had protective antibodies against HAV. No association between demographic or socioeconomic variables
and seroprotection was found. Geometric mean concentration of antibody levels against HAV was 170.5 mUI/mL (95% confidence interval: 163.2–178.2 mUI/mL).
Conclusions:
Single-dose universal hepatitis A immunization in 1-year-old children resulted in sustained immunologic
protection for up to 9 years in Argentina. These findings, along with the low current disease burden, confirm the success of the intervention.
UR - https://www.ingentaconnect.com/content/wk/inf/2016/00000035/00000012/art00020
M3 - doi:10.1097/INF.0000000000001322
UR - https://doi.org/10.1097/INF.0000000000001322
ER -